A Prospective Open-label Trial of Remicade® in Patients With Severe Exacerbation of Crohn's Disease Requiring Hospitalization-Reference-Cited by-同舟云学术

A Prospective Open-label Trial of Remicade® in Patients With Severe Exacerbation of Crohn's Disease Requiring Hospitalization

Published:2007-08 Issue:7 Volume:41 Page:677-681
ISSN:0192-0790
Container-title:Journal of Clinical Gastroenterology
language:en
Short-container-title:

Author:

Bhatia Jyoti K.,Korelitz Burton I.,Panagopoulos Georgia,Lobel Efrat,Mirsky Felice,Sultan Keith,DiSanti William,Chun Alexander,Keenan Gregory,Mamun Khalid

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology

Reference18 articles.

1. Intravenous corticotrophin vs hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up;Chun;Inflamm Bowel Dis,1998

2. Frequency of glucocorticoid resistance and dependency in Crohn's disease;Munkolm;Gut,1994

3. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease;Korelitz;Am J Gastroenterol,1993

4. Development of a Crohn's disease activity index;Best;Gastroenterology,1976

5. How to do without steroids in inflammatory bowel disease;Present;Inflamm Bowel Dis,2000

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab as Rescue Therapy for Hospitalized Patients With Crohn's Disease Failing Intravenous Corticosteroids;American Journal of Therapeutics;2020-11-13

2. Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn’s Disease to Prevent Loss of Response;Digestive Diseases and Sciences;2014-12-23

3. Infliximab vs Adalimumab for Crohn’s Disease: Perhaps too Early to Call It a Tie;Clinical Gastroenterology and Hepatology;2014-05

4. Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease;BioMed Research International;2013

5. Quaternary Chiral Center via Diastereoselective Enolate Amination Enables the Synthesis of an Anti-inflammatory Agent;Organic Process Research & Development;2009-12-03